Previous pre-clinical studies using THZ1 (which inhibits CDK12 and CDK13 as well as CDK7) have predicted benefit in other cancer types in which enhanced transcription is a major feature of the cancer phenotype19, giving scope for samuraciclib use in a wide range of cancers6,19–22. This evidence concerns the gene CDK12 and cancer.